Neuropace INC 10-Q quarterly reports

NeuroPace reported a 17% increase in revenue for Q2 2026, reaching $22.8 million, but continued to post net losses and saw a decrease in cash and cash equivalents.

NeuroPace reported a slight revenue decrease in Q1 2026 compared to the prior year, primarily due to the termination of a distribution agreement, but saw a significant improvement in gross margin.

NeuroPace, Inc. reported robust 30% revenue growth and a significant 36% reduction in net loss for Q3 2025, driven by strong RNS System sales and improved gross margins.

NeuroPace, Inc. reported a 22% revenue increase and significant gross margin expansion in Q2 2025, alongside strategic debt refinancing and progress in clinical trials for epilepsy treatments.

NeuroPace's Q1 2025 revenue increased by 24% year-over-year, driven by increased RNS System sales, while the company navigates a strategic shift with the planned expiration of its DIXI Medical distribution agreement.

NeuroPace, Inc. saw a 28% increase in revenue in the third quarter of 2024 compared to the same period last year, primarily due to increased sales of its RNS System and DIXI Medical products.

NeuroPace, Inc. announced a 21% increase in revenue for the second quarter of 2024, primarily driven by increased sales of its RNS System and DIXI Medical products.

NeuroPace, Inc. saw a 25% increase in revenue in the first quarter of 2024 compared to the same period last year, primarily due to increased sales of initial RNS System implants and DIXI Medical products.